Evogene Ltd. (EVGN) Tops Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/26/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Evogene Ltd. (EVGN) Expects Delayed Evofuel commercialization; Piper Jaffray Cuts Price Target to $8
November 19, 2015 8:56 AM ESTPiper Jaffray reiterated a Neutral rating on Evogene Ltd (NYSE: EVGN), and cut the price target to $8.00 (from $12.00), following the company's 3Q earnings report .Evogene announced results relatively in-line with Piper Jaffray's expectations, where revenue and opex were only slightly higher due to more gene discovery being done in-house. Management now expects Evofuel commercialization to be delayed,... More
